410 results about "Mycotic infection" patented technology

Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.

The present invention relates to an oral composition which includes an organoleptically suitable carrier and an amount of a terpenoid and a flavonoid, dispersed in the carrier, which is effective to prevent or treat dental caries, dental plaque formation, gingivitis, candidiasis, dental stomatitis, aphthous ulceration, or fungal infection. The invention also relates to various uses of oral compositions, containing a terpenoid, a flavonoid, or both, such uses include: inhibiting the activity of surface-bound glusosyltransferase; treating or inhibiting dental caries, gingivitis, candidiasis, denture stomatitis; inhibiting the accumulation of microorganisms on an oral surface; and/or treating or inhibiting aphthous ulcerations on an oral surface.

The present invention provides for pharmaceutical compositions that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides for a cosmetic formulation that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides a method of treating a fungal infection that includes administering (e.g., topically applying) an effective amount of the pharmaceutical composition to the tissue afflicted with the fungal infection, or the tissue at risk of being afflicted with the fungal infection.

The present invention is related to the use of novel agents effective for differential killing of abnormal cells such as cancer cells without damaging or being toxic to normal cells. Further these agents may be used for treating a host of ailments including various types of cancers, skin diseases, prevention and reversal of ageing process, prevention of inflammatory reactions, cure of bacterial infections, cure of fungal infections, etc. The agents are prepared by air oxidation of natural oils optionally in the presence of a catalyst wherein the isolated agents have Iodine value 40-60% of the starting oil, Saponification value 20-60 higher than that of the starting oil, Peroxide value 2-3 times that of the starting oil. These agents on saponification and acidification yield free fatty acids and ether linked fatty acid dimmer wherein the dimmer also acts as an active.

A method for simultaneously treating mucositis and fungal infection in a mammal in need thereof, said method comprising administering to said mammal an effective amount of an anti-mucositis and anti-fungal pharmaceutical composition consisting of a tetracycline compound in an amount that is effective to simultaneously treat mucositis and fungal infection, but has substantially no antibiotic activity.

There is disclosed a method for treating dermatologic diseases caused by microbial overgrowth or inflammation, such as psoriasis, fungal infections, eczema, dandruff, acne, genital herpes lesions, and leg ulcers. There is further disclosed an antiviral lubricating composition that is effective in preventing the transmission of the HIV virus and other sexually transmitted diseases. There is also disclosed systemic and anti-inflammatory compositions and formulations and a method for reducing tissue inflammation in tissues such as the bowel, muscle, bone, tendon and joints (e.g., arthritis).

The present invention relates to methods and devices for treating hard biological tissue (in particular, keratin-rich hard tissues) with electromagnetic energy having a frequency of at least 0.5 MHZ (megahertz) and less than 10 GHZ (gigahertz) (for example, HF, RF or microwave energy), and particularly, to methods aid devices for treating infections, for example, fungal infections of the nail.

The composition of the invention provides formulations of extract of the Musaceas plant suitable for treatment of skin and mucosal membranes. A topical composition is disclosed for the treatment of fungal infections in a subject in need thereof in which the composition has an extract of Musaceas and a carrier. The formulation can be a liquid, a lotion, a cream, a dry powder, or a suspension, and can be used as a spray, wash, rinse, bandage ointment, or lotion. A method of treating or inhibiting fungal infections in a subject in need thereof is disclosed in which the method is administering an effective amount of a composition to the subject, where the composition has Musaceas extract and a carrier.

Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses, bacteria and fungi. Accordingly, provided herein are methods of inactivating a virus, bacteria or fungus and methods of treating a viral, bacterial or fungal infection. Methods of delivering a therapeutic agent to a mammalian subject and methods of inactivating a virus in the gastrointestinal tract of an animal are also provided.

This application is directed to methods and kits for preventing the spread of sexually transmitted microorganisms among individuals. The present method is for the application of a medicament comprising an irrigant to an area of the body having, or which may have, a lesion resulting from, for example, a viral, bacteria or fungal infection, thereby damaging the microorganism within the lesion and preventing the organism from infecting human cells.

A topical sustained release delivery system for delivery of antifungal agents to the finger or toenails achieving high penetration through the nails by combining the antifungal agent with a keratolytic agent and a humectant. The pharmaceutical sustained release topical preparation is provided in a varnish or spray form for treating the nail and surrounding tissues, where the active ingredient is an antifungal agent, a keratolytic agent, or preferably a combination of an antifungal and a keratolytic agent. The composition may further comprise an antibacterial, an antiviral, an antipsoriatic agents, or combinations thereof.

The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the treatment and prophylaxis of both pulmonary and systemic fungal infections.

The invention relates to a method of testing for a mycotoxin in patient tissue or body fluid and testing for a fungal species in the patient tissue or body fluid. The method can also be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.

The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising these compounds.

A portable, small-footprint laser device contains one or more housings in which a laser energy source and an optical arrangement are disposed. The housing produces a laser beam spot that may be rotated and scanned to apply laser energy to a target area. The laser device receives treatment parameters and uses them to program a treatment regimen in which activation and movement of the housings is automated. The laser device may be used to apply a treatment regimen to a patient's hands or feet that are infected by Onychomycosis. In the treatment regimen, certain wavelengths of laser energy are applied at a predetermined duration. The treatment may be repeated, and a topical anti-fungal medication may be applied to aid in the efficacy of the treatment.

An antifungal composition and penetrating carrier system for topical treatment of dermatophytic infection and secondary bacterial infections. The antifungal composition includes various fungistatic and fungicidal essential oil components, or combinations thereof. The penetrating carrier system may include various ingredients, including a penetration enhancer, such as isopropyl myristate.

The invention relates to topical formulations and methods of use of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of Candida spp., especially C. albicans, C. glabrata, and C. tropicalis, and which pose limited risk of side effects, adverse reactions, or the development of resistant pathogens. The invention provides novel topical formulations of flucytosine designed to allow the active drug to act at the local application area, but which inhibit or moderate transdermal or transmucosal absorption of the drug, thus limiting systemic exposure.

The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections.

The invention provides methods and models for understanding how HDAC inhibitors interact with antifungal azole compounds to potentiate the activity of such compounds, using fungal strains which have selective knockouts of fungal HDAC genes. The invention further provides methods for testing antifungal agents for potential synergy with fungal HDAC inhibitors, and thus provides antifungal compound which are identified according to the methods of the invention, and methods for treatment of fungal infections using such compounds.

Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.